Organogenesis Holdings (ORGO) closed FY 2025 with fourth quarter revenue of US$225.6 million and basic EPS of US$0.28, alongside net income of US$35.1 million that capped a profitable trailing twelve month period. The company has seen quarterly revenue move from US$126.7 million and EPS of US$0.05 in Q4 2024 to US$225.6 million and EPS of US$0.28 in Q4 2025. Trailing twelve month EPS shifted from roughly flat at US$0.01 in Q4 2024 to US$0.16 in Q4 2025, setting up a results season where the quality of margin progression is front and center for investors.

See our full analysis for Organogenesis Holdings.

With the headline numbers on the table, the next step is to line them up against the most common stories about Organogenesis Holdings to see which narratives hold up and which ones the latest margin profile starts to challenge.

Profitable Trailing Year, But One Offs Matter

• On a trailing twelve month basis, Organogenesis reported US$564.2 million in revenue and US$20.0 million in net income, with basic EPS of US$0.16. That same period included a one off loss of US$16.9 million that materially affects the reported figures.
• Consensus narrative points to earnings growing about 42.7% per year with revenue up only 0.8% per year. This sits in tension with the recent mix of loss making quarters followed by a strong Q4, so investors may want to separate recurring profitability from the impact of non recurring items and shifting reimbursement incentives.

Quarterly Swing From Losses To Profits

• Within FY 2025, net income moved from losses of US$21.6 million in Q1 and US$8.0 million in Q2 to profits of US$14.5 million in Q3 and US$35.1 million in Q4, with basic EPS moving from a loss of US$0.17 to a profit of US$0.28 over the year.
• Bulls argue that upcoming CMS changes and product launches could support more durable margins. However, the sequence of losses early in 2025 alongside a 23% year over year decline in total net product revenue cited in the balanced narrative means the recent profitable quarters need to prove they can hold up once pricing pressure and reimbursement changes fully play through.

Bulls argue that the sharp swing back to profitability could be the early sign of the earnings ramp they expect, while critics will want to see several more quarters before calling it a new normal. 🐂 Organogenesis Holdings Bull Case

Valuation Sits Between Market And Peers

• The stock trades on a trailing P/E of 16.1x, below the broader US market average of 19.3x and slightly below the US Biotechs industry at 17.8x, but above the peer group average of 8.6x, with analysts citing an US$8.00 price target against a current share price of US$2.51.
• Bears highlight that modest revenue growth expectations of 0.8% per year and a P/E that is higher than peers leave less room for disappointment. The recent 23% decline in total net product revenue and 5 percentage point drop in gross margin to 73% give their case numerical backing if margin gains do not keep pace with the valuation premium to similar companies.
• Critics also point to cash use and guidance cuts in revenue, gross margin, and adjusted EBITDA as concrete figures that keep pressure on the cautious view even with the stock trading below the consensus target.

Skeptics argue that paying a higher P/E than peers only works if forecast margin gains and future growth targets are met, so they focus on revenue trends and cash use to test whether that premium is justified. 🐻 Organogenesis Holdings Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Organogenesis Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of cautious and optimistic takes feels familiar, that is the point. Move quickly, review the figures yourself, and weigh the 3 key rewards and 1 important warning sign

See What Else Is Out There

Organogenesis Holdings pairs a mixed record of loss making and profitable quarters with modest revenue expectations and a P/E that sits above close peers.

If you are uneasy about paying up for uneven earnings and softer top line figures, compare this stock with companies in the 51 high quality undervalued stocks to see if better value fits your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.